Pierpaolo Di Micco/LinkedIn
Oct 18, 2026, 12:58
Pierpaolo Di Micco: DOACs vs Vitamin K Antagonists in Long-Term Anticoagulation
Pierpaolo Di Micco, Suitability Director of the Complex Medical and Emergency Room Unit at ASL Napoli 2 Nord, shared a post on LinkedIn:
“For many years we thought that AVKs were the most known drugs in the extended treatments for patients that need prolonged anticoagulation but I do not find any Randomized Trials about this:
I’ m strongly convinced that DOACs are the most studied drugs in this field always in crucial and not easy situations as restart of treatment after major bleeding.”
Stay updated with Hemostasis Today.
-
Oct 18, 2026, 12:51Arianne Missimer: Understanding Ferritin Levels Beyond the Normal Range
-
Oct 18, 2026, 12:37Roberto C. Iglesias: Colon Cancer Prevention Beyond Supplements and Vitamins
-
Oct 18, 2026, 12:27Rafael Alejandro Camero Del Vecchio: Paroxysmal Nocturnal Hemoglobinuria Advancing Complement Inhibition with Ravulizumab
-
Oct 18, 2026, 12:26Abdul Mannan: When INR Misleads – Rethinking Bleeding Risk in Cirrhosis
-
Oct 18, 2026, 12:14Stéphane Laurent: The People and Technology Behind Safe Blood Transfusion
-
Oct 18, 2026, 12:14Abhi Kapuria: When VTE Prophylaxis Breaks Down in the ICU
-
Oct 18, 2026, 11:37Lee Anne Sorto: Beyond Compliance – Making Audits Count in Transfusion Safety
-
Oct 18, 2026, 11:26Valentina Ajello: Does ANH Benefit Women in Cardiac Surgery?
-
Oct 18, 2026, 11:06Alex Ballout: Novel FUT1 Variant Linked to a Rare H-Deficient Blood Phenotype